{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T12:08:38Z","timestamp":1779797318739,"version":"3.53.1"},"reference-count":184,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073096"],"award-info":[{"award-number":["82073096"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303362"],"award-info":[{"award-number":["82303362"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Key Research and Development Plan of Hunan Province","award":["2024DK2006"],"award-info":[{"award-number":["2024DK2006"]}]},{"DOI":"10.13039\/501100004761","name":"Provincial Natural Science Foundation of Hunan","doi-asserted-by":"crossref","award":["2025JJ30039"],"award-info":[{"award-number":["2025JJ30039"]}],"id":[{"id":"10.13039\/501100004761","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004761","name":"Provincial Natural Science Foundation of Hunan","doi-asserted-by":"crossref","award":["2025JJ60852"],"award-info":[{"award-number":["2025JJ60852"]}],"id":[{"id":"10.13039\/501100004761","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Scientific Research Program of FuRong Laboratory","award":["No. 2023SK2085"],"award-info":[{"award-number":["No. 2023SK2085"]}]},{"name":"Changsha Municipal Natural Science Foundation","award":["kq2403124"],"award-info":[{"award-number":["kq2403124"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40259-026-00771-3","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T15:44:06Z","timestamp":1773330246000},"page":"433-458","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["In Vivo T-Cell Engineering: Revolution in Delivery Strategies and Clinical Translation"],"prefix":"10.1007","volume":"40","author":[{"given":"Xiaoyi","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinmiao","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5547-907X","authenticated-orcid":false,"given":"Minghua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"771_CR1","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","volume":"319","author":"SA Rosenberg","year":"1988","unstructured":"Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med. 1988;319:1676\u201380. https:\/\/doi.org\/10.1056\/NEJM198812223192527.","journal-title":"N Engl J Med"},{"key":"771_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242115688","volume":"24","author":"AC Uscanga-Palomeque","year":"2023","unstructured":"Uscanga-Palomeque AC, Ch\u00e1vez-Escamilla AK, Alvizo-B\u00e1ez CA, Saavedra-Alonso S, Terrazas-Armend\u00e1riz LD, Tamez-Guerra RS, et al. CAR-T cell therapy: from the shop to cancer therapy. Int J Mol Sci. 2023;24:15688. https:\/\/doi.org\/10.3390\/ijms242115688.","journal-title":"Int J Mol Sci"},{"key":"771_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-024-00551-1","volume":"13","author":"PL Zinzani","year":"2024","unstructured":"Zinzani PL, Mu\u00f1oz J, Trotman J. Current and future therapies for follicular lymphoma. Exp Hematol Oncol. 2024;13:87. https:\/\/doi.org\/10.1186\/s40164-024-00551-1.","journal-title":"Exp Hematol Oncol"},{"key":"771_CR4","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1182\/blood.2023022922","volume":"145","author":"A Rampotas","year":"2025","unstructured":"Rampotas A, Roddie C. The present and future of CAR T-cell therapy for adult B-cell ALL. Blood. 2025;145:1485\u201397. https:\/\/doi.org\/10.1182\/blood.2023022922.","journal-title":"Blood"},{"key":"771_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.809754","volume":"12","author":"T Xin","year":"2022","unstructured":"Xin T, Cheng L, Zhou C, Zhao Y, Hu Z, Wu X. In-vivo induced CAR-T cell for the potential breakthrough to overcome the barriers of current CAR-T cell therapy. Front Oncol. 2022;12:809754. https:\/\/doi.org\/10.3389\/fonc.2022.809754.","journal-title":"Front Oncol"},{"key":"771_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01663-0","volume":"21","author":"J Lu","year":"2022","unstructured":"Lu J, Jiang G. The journey of CAR-T therapy in hematological malignancies. Mol Cancer. 2022;21:194. https:\/\/doi.org\/10.1186\/s12943-022-01663-0.","journal-title":"Mol Cancer"},{"key":"771_CR7","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adf3700","volume":"9","author":"E Baulu","year":"2023","unstructured":"Baulu E, Gardet C, Chuvin N, Depil S. TCR-engineered T cell therapy in solid tumors: state of the art and perspectives. Sci Adv. 2023;9:eadf3700. https:\/\/doi.org\/10.1126\/sciadv.adf3700.","journal-title":"Sci Adv"},{"key":"771_CR8","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/S0140-6736(24)00319-2","volume":"403","author":"SP D\u2019Angelo","year":"2024","unstructured":"D\u2019Angelo SP, Araujo DM, Abdul Razak AR, Agulnik M, Attia S, Blay J-Y, et al. Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial. Lancet. 2024;403:1460\u201371. https:\/\/doi.org\/10.1016\/S0140-6736(24)00319-2.","journal-title":"Lancet"},{"key":"771_CR9","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_397912","author":"ERS Cliff","year":"2023","unstructured":"Cliff ERS, Kelkar AH, Russler-Germain DA, Tessema FA, Raymakers AJN, Feldman WB, et al. High cost of chimeric antigen receptor T-cells: challenges and solutions. Am Soc Clin Oncol Educ Book. 2023. https:\/\/doi.org\/10.1200\/EDBK_397912.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"771_CR10","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1038\/s41375-023-02018-4","volume":"37","author":"S Li","year":"2023","unstructured":"Li S, Wang X, Liu L, Liu J, Rao J, Yuan Z, et al. CD7 targeted \u201coff-the-shelf\u201d CAR-T demonstrates robust in vivo expansion and high efficacy in the treatment of patients with relapsed and refractory T cell malignancies. Leukemia. 2023;37:2176\u201386. https:\/\/doi.org\/10.1038\/s41375-023-02018-4.","journal-title":"Leukemia"},{"key":"771_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2025.07.046","author":"Z Wu","year":"2025","unstructured":"Wu Z, Shi J, Lamao Q, Qiu Y, Yang J, Liu Y, et al. Glycan shielding enables TCR-sufficient allogeneic CAR-T therapy. Cell. 2025. https:\/\/doi.org\/10.1016\/j.cell.2025.07.046.","journal-title":"Cell"},{"key":"771_CR12","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1016\/j.ymthe.2022.05.018","volume":"30","author":"A Michels","year":"2022","unstructured":"Michels A, Ho N, Buchholz CJ. Precision medicine: in vivo CAR therapy as a showcase for receptor-targeted vector platforms. Mol Ther. 2022;30:2401\u201315. https:\/\/doi.org\/10.1016\/j.ymthe.2022.05.018.","journal-title":"Mol Ther"},{"key":"771_CR13","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12967-024-06052-3","volume":"23","author":"E Pinto","year":"2025","unstructured":"Pinto E, Lione L, Compagnone M, Paccagnella M, Salvatori E, Greco M, et al. From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy. J Transl Med. 2025;23:10. https:\/\/doi.org\/10.1186\/s12967-024-06052-3.","journal-title":"J Transl Med"},{"key":"771_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-025-01291-5","author":"A Bot","year":"2025","unstructured":"Bot A, Scharenberg A, Friedman K, Guey L, Hofmeister R, Andorko JI, et al. In vivo chimeric antigen receptor (CAR)-T cell therapy. Nat Rev Drug Discov. 2025. https:\/\/doi.org\/10.1038\/s41573-025-01291-5.","journal-title":"Nat Rev Drug Discov"},{"key":"771_CR15","doi-asserted-by":"publisher","first-page":"4676","DOI":"10.1182\/bloodadvances.2025015928","volume":"9","author":"JC Panetta","year":"2025","unstructured":"Panetta JC, Talleur AC, Naik S, Gottschalk S, Leggas M. Age-adjusted dosing of fludarabine for lymphodepletion in CAR T-cell therapy: a clinical trial simulation study. Blood Adv. 2025;9:4676\u201382. https:\/\/doi.org\/10.1182\/bloodadvances.2025015928.","journal-title":"Blood Adv"},{"key":"771_CR16","doi-asserted-by":"publisher","first-page":"4937","DOI":"10.1016\/j.ymthe.2025.06.036","volume":"33","author":"JI Andorko","year":"2025","unstructured":"Andorko JI, Russell RM, Schnepp BC, Grubaugh D, Mullen KF, Wakabayashi A, et al. Targeted in vivo delivery of genetic medicines utilizing an engineered lentiviral vector platform results in CAR T and NK cell generation. Mol Ther. 2025;33:4937\u201352. https:\/\/doi.org\/10.1016\/j.ymthe.2025.06.036.","journal-title":"Mol Ther"},{"key":"771_CR17","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/s41571-022-00607-3","volume":"19","author":"L Amini","year":"2022","unstructured":"Amini L, Silbert SK, Maude SL, Nastoupil LJ, Ramos CA, Brentjens RJ, et al. Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion. Nat Rev Clin Oncol. 2022;19:342\u201355. https:\/\/doi.org\/10.1038\/s41571-022-00607-3.","journal-title":"Nat Rev Clin Oncol"},{"key":"771_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202303215","volume":"10","author":"Z Chen","year":"2023","unstructured":"Chen Z, Hu Y, Mei H. Advances in CAR\u2010engineered immune cell generation: engineering approaches and sourcing strategies. Adv Sci. 2023;10:2303215. https:\/\/doi.org\/10.1002\/advs.202303215.","journal-title":"Adv Sci"},{"key":"771_CR19","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/978-1-0716-3682-4_17","volume":"2766","author":"S Liu","year":"2024","unstructured":"Liu S. Lentiviral production platform. Methods Mol Biol. 2024;2766:163\u20138. https:\/\/doi.org\/10.1007\/978-1-0716-3682-4_17.","journal-title":"Methods Mol Biol"},{"key":"771_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14081630","volume":"14","author":"M Yang","year":"2022","unstructured":"Yang M, Olaoba OT, Zhang C, Kimchi ET, Staveley-O\u2019Carroll KF, Li G. Cancer immunotherapy and delivery system: an update. Pharmaceutics. 2022;14:1630. https:\/\/doi.org\/10.3390\/pharmaceutics14081630.","journal-title":"Pharmaceutics"},{"key":"771_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2025.101612","volume":"12","author":"Z Song","year":"2025","unstructured":"Song Z, Zhou Y, Wang B, Geng Y, Tang G, Wang Y, et al. In vivo production of CAR T cell: opportunities and challenges. Genes Dis. 2025;12:101612. https:\/\/doi.org\/10.1016\/j.gendis.2025.101612.","journal-title":"Genes Dis"},{"key":"771_CR22","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/j.jcyt.2024.06.010","volume":"26","author":"H He","year":"2024","unstructured":"He H, Vedia RA, Lu S, Li Q, Cox KR, St. John L, et al. Hu8F4-CAR T cells with mutated Fc spacer segment improve target specificity and mediate anti-leukemia activity in vivo. Cytotherapy. 2024;26:1331\u201340. https:\/\/doi.org\/10.1016\/j.jcyt.2024.06.010.","journal-title":"Cytotherapy"},{"key":"771_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2026.117673","volume":"245","author":"Q Zhang","year":"2026","unstructured":"Zhang Q, Chiang Z-C, Weng H, Chen X, Zhao N, Yan C, et al. Enhancement of B7-H3 chimeric antigen receptor-T cell efficacy via the coexistence effect of IL-7, IL-15 and CCL19 for pancreatic and lung xenograft tumors. Biochem Pharmacol. 2026;245:117673. https:\/\/doi.org\/10.1016\/j.bcp.2026.117673.","journal-title":"Biochem Pharmacol"},{"key":"771_CR24","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.tips.2024.03.004","volume":"45","author":"L Short","year":"2024","unstructured":"Short L, Holt RA, Cullis PR, Evgin L. Direct in vivo CAR T cell engineering. Trends Pharmacol Sci. 2024;45:406\u201318. https:\/\/doi.org\/10.1016\/j.tips.2024.03.004.","journal-title":"Trends Pharmacol Sci"},{"key":"771_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02512-4","volume":"10","author":"Q Hu","year":"2025","unstructured":"Hu Q, Zhao H, Zhou K, Tian X, Wang Q, Hua X, et al. Scarless circular mRNA-based CAR-T cell therapy elicits superior antitumor efficacy. Sig Transduct Target Ther. 2025;10:411. https:\/\/doi.org\/10.1038\/s41392-025-02512-4.","journal-title":"Sig Transduct Target Ther"},{"key":"771_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02269-w","volume":"10","author":"I Zugasti","year":"2025","unstructured":"Zugasti I, Espinosa-Aroca L, Fidyt K, Mulens-Arias V, Diaz-Beya M, Juan M, et al. CAR-T cell therapy for cancer: current challenges and future directions. Sig Transduct Target Ther. 2025;10:210. https:\/\/doi.org\/10.1038\/s41392-025-02269-w.","journal-title":"Sig Transduct Target Ther"},{"key":"771_CR27","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","volume":"602","author":"JJ Melenhorst","year":"2022","unstructured":"Melenhorst JJ, Chen GM, Wang M, Porter DL, Chen C, Collins MA, et al. Decade-long leukaemia remissions with persistence of CD4+ CAR T cells. Nature. 2022;602:503\u20139. https:\/\/doi.org\/10.1038\/s41586-021-04390-6.","journal-title":"Nature"},{"key":"771_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-011759","volume":"13","author":"JF Bimbo","year":"2025","unstructured":"Bimbo JF, Van Diest E, Murphy DE, Ashoti A, Evers MJW, Narayanavari SA, et al. T cell-specific non-viral DNA delivery and in vivo CAR-T generation using targeted lipid nanoparticles. J Immunother Cancer. 2025;13:e011759. https:\/\/doi.org\/10.1136\/jitc-2025-011759.","journal-title":"J Immunother Cancer"},{"key":"771_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2019.101370","volume":"34","author":"G Elia","year":"2020","unstructured":"Elia G, Ferrari SM, Galdiero MR, Ragusa F, Paparo SR, Ruffilli I, et al. New insight in endocrine-related adverse events associated to immune checkpoint blockade. Best Pract Res Clin Endocrinol Metab. 2020;34:101370. https:\/\/doi.org\/10.1016\/j.beem.2019.101370.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"771_CR30","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jconrel.2024.06.023","volume":"372","author":"S Soroudi","year":"2024","unstructured":"Soroudi S, Jaafari MR, Arabi L. Lipid nanoparticle (LNP) mediated mRNA delivery in cardiovascular diseases: advances in genome editing and CAR T cell therapy. J Control Release. 2024;372:113\u201340. https:\/\/doi.org\/10.1016\/j.jconrel.2024.06.023.","journal-title":"J Control Release"},{"key":"771_CR31","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/978-1-4939-9139-6_2","volume-title":"Adeno-associated virus vectors [Internet]","author":"A Patel","year":"2019","unstructured":"Patel A, Zhao J, Duan D, Lai Y. Design of AAV Vectors for delivery of large or multiple transgenes. In: Castle MJ, editor. Adeno-associated virus vectors [Internet]. New York: Springer; 2019. p. 19\u201333. https:\/\/doi.org\/10.1007\/978-1-4939-9139-6_2."},{"key":"771_CR32","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1038\/s41586-025-09489-8","volume":"646","author":"NH Knudsen","year":"2025","unstructured":"Knudsen NH, Escobar G, Korell F, Kienka T, Nobrega C, Anderson S, et al. In vivo CRISPR screens identify modifiers of CAR T cell function in myeloma. Nature. 2025;646:953\u201362. https:\/\/doi.org\/10.1038\/s41586-025-09489-8.","journal-title":"Nature"},{"key":"771_CR33","doi-asserted-by":"publisher","first-page":"3732","DOI":"10.1038\/s41598-025-87941-5","volume":"15","author":"T-T Xu","year":"2025","unstructured":"Xu T-T, Wang Y-F, Yuan J-J, Mi C-L, Geng S-L, Wang X, et al. Optimization of the intron sequences combined with the CMV promoter increases recombinant protein expression in CHO cells. Sci Rep. 2025;15:3732. https:\/\/doi.org\/10.1038\/s41598-025-87941-5.","journal-title":"Sci Rep"},{"key":"771_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0232915","volume":"15","author":"SMAH Rad","year":"2020","unstructured":"Rad SMAH, Poudel A, Tan GMY, McLellan AD. Promoter choice: Who should drive the CAR in T cells? Ramos JW, editor. PLoS ONE. 2020;15:e0232915. https:\/\/doi.org\/10.1371\/journal.pone.0232915.","journal-title":"PLoS ONE"},{"key":"771_CR35","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adn6509","volume":"9","author":"RP Patel","year":"2024","unstructured":"Patel RP, Ghilardi G, Zhang Y, Chiang Y-H, Xie W, Guruprasad P, et al. CD5 deletion enhances the antitumor activity of adoptive T cell therapies. Sci Immunol. 2024;9:eadn6509. https:\/\/doi.org\/10.1126\/sciimmunol.adn6509.","journal-title":"Sci Immunol"},{"key":"771_CR36","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13045-024-01633-7","volume":"17","author":"W Zhang","year":"2024","unstructured":"Zhang W, Huang X. In vivo gene editing and in situ generation of chimeric antigen receptor cells for next-generation cancer immunotherapy. J Hematol Oncol. 2024;17:110. https:\/\/doi.org\/10.1186\/s13045-024-01633-7.","journal-title":"J Hematol Oncol"},{"key":"771_CR37","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/s41467-026-68434-z","volume":"17","author":"F Port","year":"2026","unstructured":"Port F, Buhmann MA, Zhou J, Stricker M, Vaughan-Brown A, Michalsen A-C, et al. Improved in vivo gene knockout with high specificity using multiplexed Cas12a sgRNAs. Nat Commun. 2026;17:877. https:\/\/doi.org\/10.1038\/s41467-026-68434-z.","journal-title":"Nat Commun"},{"key":"771_CR38","doi-asserted-by":"publisher","first-page":"11077","DOI":"10.1038\/s41467-025-67243-0","volume":"16","author":"D Macak","year":"2025","unstructured":"Macak D, Kanis P, Riesenberg S. Repurposing clinically safe drugs for DNA repair pathway choice in CRISPR genome editing and synthetic lethality. Nat Commun. 2025;16:11077. https:\/\/doi.org\/10.1038\/s41467-025-67243-0.","journal-title":"Nat Commun"},{"key":"771_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2022.121876","volume":"291","author":"K Huang","year":"2022","unstructured":"Huang K, Zapata D, Tang Y, Teng Y, Li Y. In vivo delivery of CRISPR-Cas9 genome editing components for therapeutic applications. Biomaterials. 2022;291:121876. https:\/\/doi.org\/10.1016\/j.biomaterials.2022.121876.","journal-title":"Biomaterials"},{"key":"771_CR40","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba7365","volume":"367","author":"EA Stadtmauer","year":"2020","unstructured":"Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, et al. CRISPR-engineered T cells in patients with refractory cancer. Science. 2020;367:eaba7365. https:\/\/doi.org\/10.1126\/science.aba7365.","journal-title":"Science"},{"key":"771_CR41","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/s41588-021-00838-7","volume":"53","author":"ML Leibowitz","year":"2021","unstructured":"Leibowitz ML, Papathanasiou S, Doerfler PA, Blaine LJ, Sun L, Yao Y, et al. Chromothripsis as an on-target consequence of CRISPR\u2013Cas9 genome editing. Nat Genet. 2021;53:895\u2013905. https:\/\/doi.org\/10.1038\/s41588-021-00838-7.","journal-title":"Nat Genet"},{"key":"771_CR42","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/nbt.4192","volume":"36","author":"M Kosicki","year":"2018","unstructured":"Kosicki M, Tomberg K, Bradley A. Repair of double-strand breaks induced by CRISPR\u2013Cas9 leads to large deletions and complex rearrangements. Nat Biotechnol. 2018;36:765\u201371. https:\/\/doi.org\/10.1038\/nbt.4192.","journal-title":"Nat Biotechnol"},{"key":"771_CR43","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa2300709","volume":"389","author":"R Chiesa","year":"2023","unstructured":"Chiesa R, Syed F, Zhan H, Etuk A, Gkazi SA, Preece R, et al. Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia. N Engl J Med. 2023;389:899\u2013910. https:\/\/doi.org\/10.1056\/NEJMoa2300709.","journal-title":"N Engl J Med"},{"key":"771_CR44","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41551-023-01026-0","volume":"7","author":"KA Everette","year":"2023","unstructured":"Everette KA, Newby GA, Levine RM, Mayberry K, Jang Y, Mayuranathan T, et al. Ex vivo prime editing of patient haematopoietic stem cells rescues sickle-cell disease phenotypes after engraftment in mice. Nat Biomed Eng. 2023;7:616\u201328. https:\/\/doi.org\/10.1038\/s41551-023-01026-0.","journal-title":"Nat Biomed Eng"},{"key":"771_CR45","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/s41587-023-01915-4","volume":"42","author":"M Fiumara","year":"2024","unstructured":"Fiumara M, Ferrari S, Omer-Javed A, Beretta S, Albano L, Canarutto D, et al. Genotoxic effects of base and prime editing in human hematopoietic stem cells. Nat Biotechnol. 2024;42:877\u201391. https:\/\/doi.org\/10.1038\/s41587-023-01915-4.","journal-title":"Nat Biotechnol"},{"key":"771_CR46","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/s41587-024-02320-1","volume":"42","author":"SR McCutcheon","year":"2024","unstructured":"McCutcheon SR, Rohm D, Iglesias N, Gersbach CA. Epigenome editing technologies for discovery and medicine. Nat Biotechnol. 2024;42:1199\u2013217. https:\/\/doi.org\/10.1038\/s41587-024-02320-1.","journal-title":"Nat Biotechnol"},{"key":"771_CR47","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/s41588-024-01706-w","volume":"56","author":"C Policarpi","year":"2024","unstructured":"Policarpi C, Munaf\u00f2 M, Tsagkris S, Carlini V, Hackett JA. Systematic epigenome editing captures the context-dependent instructive function of chromatin modifications. Nat Genet. 2024;56:1168\u201380. https:\/\/doi.org\/10.1038\/s41588-024-01706-w.","journal-title":"Nat Genet"},{"key":"771_CR48","doi-asserted-by":"publisher","first-page":"9901","DOI":"10.1093\/nar\/gkx578","volume":"45","author":"H O\u2019Geen","year":"2017","unstructured":"O\u2019Geen H, Ren C, Nicolet CM, Perez AA, Halmai J, Le VM, et al. dCas9-based epigenome editing suggests acquisition of histone methylation is not sufficient for target gene repression. Nucleic Acids Res. 2017;45:9901\u201316. https:\/\/doi.org\/10.1093\/nar\/gkx578.","journal-title":"Nucleic Acids Res"},{"key":"771_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01559-z","volume":"21","author":"A Dimitri","year":"2022","unstructured":"Dimitri A, Herbst F, Fraietta JA. Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing. Mol Cancer. 2022;21:78. https:\/\/doi.org\/10.1186\/s12943-022-01559-z.","journal-title":"Mol Cancer"},{"key":"771_CR50","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.ccell.2025.03.019","volume":"43","author":"B Du","year":"2025","unstructured":"Du B, Qin J, Lin B, Zhang J, Li D, Liu M. CAR-T therapy in solid tumors. Cancer Cell. 2025;43:665\u201379. https:\/\/doi.org\/10.1016\/j.ccell.2025.03.019.","journal-title":"Cancer Cell"},{"key":"771_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.biotechadv.2025.108649","volume":"83","author":"Y Zheng","year":"2025","unstructured":"Zheng Y, Zhu Q, Li X, Ge T, Wang S, Jia R, et al. Epigenetic reprogramming holds promise in enhancing anti-tumor efficacy of CAR T cell therapy. Biotechnol Adv. 2025;83:108649. https:\/\/doi.org\/10.1016\/j.biotechadv.2025.108649.","journal-title":"Biotechnol Adv"},{"key":"771_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-025-01509-2","author":"JP Murad","year":"2025","unstructured":"Murad JP, Christian L, Rosa R, Ren Y, Buckley AJ, Lee EHJ, et al. Solid tumour CAR-T cells engineered with fusion proteins targeting PD-L1 for localized IL-12 delivery. Nat Biomed Eng [Internet]. 2025. https:\/\/doi.org\/10.1038\/s41551-025-01509-2.","journal-title":"Nat Biomed Eng [Internet]."},{"key":"771_CR53","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.omtn.2023.03.018","volume":"32","author":"M Trist\u00e1n-Manzano","year":"2023","unstructured":"Trist\u00e1n-Manzano M, Maldonado-P\u00e9rez N, Justicia-Lirio P, Cortijo-Gutierr\u00e9z M, Trist\u00e1n-Ramos P, Blanco-Ben\u00edtez C, et al. Lentiviral vectors for inducible, transactivator-free advanced therapy medicinal products: application to CAR-T cells. Mol Ther Nucleic Acids. 2023;32:322\u201339. https:\/\/doi.org\/10.1016\/j.omtn.2023.03.018.","journal-title":"Mol Ther Nucleic Acids"},{"key":"771_CR54","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1016\/j.cell.2025.02.035","volume":"188","author":"L Liu","year":"2025","unstructured":"Liu L, He P, Wang Y, Ma F, Li D, Bai Z, et al. Engineering sonogenetic EchoBack-CAR T cells. Cell. 2025;188:2621-2636.e20. https:\/\/doi.org\/10.1016\/j.cell.2025.02.035.","journal-title":"Cell"},{"key":"771_CR55","doi-asserted-by":"publisher","first-page":"3546","DOI":"10.1016\/j.ymthe.2025.04.037","volume":"33","author":"HTX Nguyen","year":"2025","unstructured":"Nguyen HTX, Kim B-G, Myers JT, Yan H, Kumar S, Eid S, et al. Engineering TME-gated inducible CAR-T cell therapy for solid tumors. Mol Ther. 2025;33:3546\u201358. https:\/\/doi.org\/10.1016\/j.ymthe.2025.04.037.","journal-title":"Mol Ther"},{"key":"771_CR56","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1038\/s41551-025-01373-0","volume":"9","author":"Y Liu","year":"2025","unstructured":"Liu Y, Liu Q, Zhang B, Chen S, Shen Y, Li Z, et al. Generation of tolerogenic antigen-presenting cells in vivo via the delivery of mRNA encoding PDL1 within lipid nanoparticles. Nat Biomed Eng. 2025;9:1320\u201334. https:\/\/doi.org\/10.1038\/s41551-025-01373-0.","journal-title":"Nat Biomed Eng"},{"key":"771_CR57","doi-asserted-by":"publisher","DOI":"10.1126\/science.adl4237","volume":"386","author":"MS Simic","year":"2024","unstructured":"Simic MS, Watchmaker PB, Gupta S, Wang Y, Sagan SA, Duecker J, et al. Programming tissue-sensing T cells that deliver therapies to the brain. Science. 2024;386:eadl4237. https:\/\/doi.org\/10.1126\/science.adl4237.","journal-title":"Science"},{"key":"771_CR58","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41422-023-00828-w","volume":"33","author":"Z Zhao","year":"2023","unstructured":"Zhao Z, Sadelain M. CAR T cell design: approaching the elusive AND-gate. Cell Res. 2023;33:739\u201340. https:\/\/doi.org\/10.1038\/s41422-023-00828-w.","journal-title":"Cell Res"},{"key":"771_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102195","volume":"6","author":"B-H Yang","year":"2025","unstructured":"Yang B-H, Gutierrez A, Liao A, Shirinbak S, Gaertner B, Pribadi M, et al. iPSC-derived trimodal T cells engineered with CAR, TCR, and hnCD16 modalities can overcome antigen escape in heterogeneous tumors. Cell Rep Med. 2025;6:102195. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102195.","journal-title":"Cell Rep Med"},{"key":"771_CR60","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/nbt.2678","volume":"31","author":"M Themeli","year":"2013","unstructured":"Themeli M, Kloss CC, Ciriello G, Fedorov VD, Perna F, Gonen M, et al. Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. Nat Biotechnol. 2013;31:928\u201333. https:\/\/doi.org\/10.1038\/nbt.2678.","journal-title":"Nat Biotechnol"},{"key":"771_CR61","doi-asserted-by":"publisher","first-page":"5980","DOI":"10.1016\/j.cell.2025.07.009","volume":"188","author":"R Mout","year":"2025","unstructured":"Mout R, Jing R, Tanaka-Yano M, Egan ED, Eisenach H, Kononov MA, et al. Design of soluble Notch agonists that drive T cell development and boost immunity. Cell. 2025;188:5980-5994.e28. https:\/\/doi.org\/10.1016\/j.cell.2025.07.009.","journal-title":"Cell"},{"key":"771_CR62","doi-asserted-by":"publisher","first-page":"16982","DOI":"10.1021\/acsnano.1c04996","volume":"15","author":"R Tenchov","year":"2021","unstructured":"Tenchov R, Bird R, Curtze AE, Zhou Q. Lipid nanoparticles\u2500from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement. ACS Nano. 2021;15:16982\u20137015. https:\/\/doi.org\/10.1021\/acsnano.1c04996.","journal-title":"ACS Nano"},{"key":"771_CR63","doi-asserted-by":"publisher","first-page":"3772","DOI":"10.1016\/j.ymthe.2024.09.019","volume":"32","author":"Z Chen","year":"2024","unstructured":"Chen Z, Shu J, Hu Y, Mei H. Synergistic integration of mRNA-LNP with CAR-engineered immune cells: pioneering progress in immunotherapy. Mol Ther. 2024;32:3772\u201392. https:\/\/doi.org\/10.1016\/j.ymthe.2024.09.019.","journal-title":"Mol Ther"},{"key":"771_CR64","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41596-022-00755-x","volume":"18","author":"X Wang","year":"2023","unstructured":"Wang X, Liu S, Sun Y, Yu X, Lee SM, Cheng Q, et al. Preparation of selective organ-targeting (SORT) lipid nanoparticles (LNPs) using multiple technical methods for tissue-specific mRNA delivery. Nat Protoc. 2023;18:265\u201391. https:\/\/doi.org\/10.1038\/s41596-022-00755-x.","journal-title":"Nat Protoc"},{"key":"771_CR65","doi-asserted-by":"publisher","DOI":"10.3390\/v11020102","volume":"11","author":"J Rabinowitz","year":"2019","unstructured":"Rabinowitz J, Chan YK, Samulski RJ. Adeno-associated virus (AAV) versus immune response. Viruses. 2019;11:102. https:\/\/doi.org\/10.3390\/v11020102.","journal-title":"Viruses"},{"key":"771_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00508-1","volume":"11","author":"W Nawaz","year":"2021","unstructured":"Nawaz W, Huang B, Xu S, Li Y, Zhu L, Yiqiao H, et al. AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia. Blood Cancer J. 2021;11:119. https:\/\/doi.org\/10.1038\/s41408-021-00508-1.","journal-title":"Blood Cancer J"},{"key":"771_CR67","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.ymthe.2024.02.002","volume":"32","author":"J Hordeaux","year":"2024","unstructured":"Hordeaux J, Lamontagne RJ, Song C, Buchlis G, Dyer C, Buza EL, et al. High-dose systemic adeno-associated virus vector administration causes liver and sinusoidal endothelial cell injury. Mol Ther. 2024;32:952\u201368. https:\/\/doi.org\/10.1016\/j.ymthe.2024.02.002.","journal-title":"Mol Ther"},{"key":"771_CR68","doi-asserted-by":"publisher","first-page":"4953","DOI":"10.1016\/j.ymthe.2025.07.006","volume":"33","author":"T Coradin","year":"2025","unstructured":"Coradin T, Keating AL, Barnard AR, Whilding L, Pombal D, Hannoun Z, et al. Efficient in vivo generation of CAR T cells using a retargeted fourth-generation lentiviral vector. Mol Ther. 2025;33:4953\u201367. https:\/\/doi.org\/10.1016\/j.ymthe.2025.07.006.","journal-title":"Mol Ther"},{"key":"771_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40788-8","volume":"14","author":"D Strebinger","year":"2023","unstructured":"Strebinger D, Frangieh CJ, Friedrich MJ, Faure G, Macrae RK, Zhang F. Cell type-specific delivery by modular envelope design. Nat Commun. 2023;14:5141. https:\/\/doi.org\/10.1038\/s41467-023-40788-8.","journal-title":"Nat Commun"},{"key":"771_CR70","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/nnano.2017.57","volume":"12","author":"TT Smith","year":"2017","unstructured":"Smith TT, Stephan SB, Moffett HF, McKnight LE, Ji W, Reiman D, et al. In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers. Nat Nanotechnol. 2017;12:813\u201320. https:\/\/doi.org\/10.1038\/nnano.2017.57.","journal-title":"Nat Nanotechnol"},{"key":"771_CR71","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/s44222-024-00269-z","volume":"3","author":"C Xu","year":"2025","unstructured":"Xu C, Ivanovski S. Clinical translation of personalized bioengineered implant scaffolds. Nat Rev Bioeng. 2025;3:390\u2013407. https:\/\/doi.org\/10.1038\/s44222-024-00269-z.","journal-title":"Nat Rev Bioeng"},{"key":"771_CR72","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1038\/s41563-025-02212-y","volume":"24","author":"D Wu","year":"2025","unstructured":"Wu D, Eugenis I, Hu C, Kim S, Kanugovi A, Yue S, et al. Bioinstructive scaffolds enhance stem cell engraftment for functional tissue regeneration. Nat Mater. 2025;24:1364\u201374. https:\/\/doi.org\/10.1038\/s41563-025-02212-y.","journal-title":"Nat Mater"},{"key":"771_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.114291","volume":"388","author":"S Lu","year":"2025","unstructured":"Lu S, Miao Y, Wang D, Xu D, Liu R, Liu X, et al. Engineered tumor-symbiotic bacterial membrane nanovesicles enable precise immuno-chemotherapy of colorectal cancer. J Control Release. 2025;388:114291. https:\/\/doi.org\/10.1016\/j.jconrel.2025.114291.","journal-title":"J Control Release"},{"key":"771_CR74","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.scib.2023.11.055","volume":"69","author":"G Zhao","year":"2024","unstructured":"Zhao G, Zhang Y, Xu C-F, Wang J. In vivo production of CAR-T cells using virus-mimetic fusogenic nanovesicles. Sci Bull. 2024;69:354\u201366. https:\/\/doi.org\/10.1016\/j.scib.2023.11.055.","journal-title":"Sci Bull"},{"key":"771_CR75","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1038\/s41587-023-02085-z","volume":"42","author":"JR Hamilton","year":"2024","unstructured":"Hamilton JR, Chen E, Perez BS, Sandoval Espinoza CR, Kang MH, Trinidad M, et al. In vivo human T cell engineering with enveloped delivery vehicles. Nat Biotechnol. 2024;42:1684\u201392. https:\/\/doi.org\/10.1038\/s41587-023-02085-z.","journal-title":"Nat Biotechnol"},{"key":"771_CR76","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.1016\/S2352-3026(24)00273-4","volume":"12","author":"G Agliardi","year":"2025","unstructured":"Agliardi G, Dias J, Rampotas A, Garcia J, Roddie C. Accelerating and optimising CAR T-cell manufacture to deliver better patient products. Lancet Haematol. 2025;12:e57-67. https:\/\/doi.org\/10.1016\/S2352-3026(24)00273-4.","journal-title":"Lancet Haematol"},{"key":"771_CR77","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41577-025-01174-1","volume":"25","author":"Y-R Li","year":"2025","unstructured":"Li Y-R, Zhu Y, Halladay T, Yang L. In vivo CAR engineering for immunotherapy. Nat Rev Immunol. 2025;25:725\u201344. https:\/\/doi.org\/10.1038\/s41577-025-01174-1.","journal-title":"Nat Rev Immunol"},{"key":"771_CR78","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1126\/science.abg6155","volume":"373","author":"M Segel","year":"2021","unstructured":"Segel M, Lash B, Song J, Ladha A, Liu CC, Jin X, et al. Mammalian retrovirus-like protein PEG10 packages its own mRNA and can be pseudotyped for mRNA delivery. Science. 2021;373:882\u20139. https:\/\/doi.org\/10.1126\/science.abg6155.","journal-title":"Science"},{"key":"771_CR79","doi-asserted-by":"publisher","DOI":"10.1088\/1361-6528\/add482","volume":"36","author":"Z Zhao","year":"2025","unstructured":"Zhao Z, Li M, Zheng X, Gao P, Huang C, Yu Q, et al. mRNA lipid nanoparticles in CAR-T therapy: a novel strategy to improve efficacy. Nanotechnology. 2025;36:222003. https:\/\/doi.org\/10.1088\/1361-6528\/add482.","journal-title":"Nanotechnology"},{"key":"771_CR80","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1021\/acs.nanolett.9b04246","volume":"20","author":"MM Billingsley","year":"2020","unstructured":"Billingsley MM, Singh N, Ravikumar P, Zhang R, June CH, Mitchell MJ. Ionizable lipid nanoparticle-mediated mRNA delivery for human CAR T cell engineering. Nano Lett. 2020;20:1578\u201389. https:\/\/doi.org\/10.1021\/acs.nanolett.9b04246.","journal-title":"Nano Lett"},{"key":"771_CR81","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.jconrel.2022.08.033","volume":"350","author":"J Zhou","year":"2022","unstructured":"Zhou J, Sun L, Jia Y, Wang Z, Luo T, Tan J, et al. Lipid nanoparticles produce chimeric antigen receptor T cells with interleukin-6 knockdown in vivo. J Control Release. 2022;350:298\u2013307. https:\/\/doi.org\/10.1016\/j.jconrel.2022.08.033.","journal-title":"J Control Release"},{"key":"771_CR82","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.1016\/j.ymthe.2025.03.018","volume":"33","author":"TE Papp","year":"2025","unstructured":"Papp TE, Zeng J, Shahnawaz H, Akyianu A, Breda L, Yadegari A, et al. CD47 peptide-cloaked lipid nanoparticles promote cell-specific mRNA delivery. Mol Ther. 2025;33:3195\u2013208. https:\/\/doi.org\/10.1016\/j.ymthe.2025.03.018.","journal-title":"Mol Ther"},{"key":"771_CR83","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1126\/science.ads8473","volume":"388","author":"TL Hunter","year":"2025","unstructured":"Hunter TL, Bao Y, Zhang Y, Matsuda D, Riener R, Wang A, et al. In vivo CAR T cell generation to treat cancer and autoimmune disease. Science. 2025;388:1311\u20137. https:\/\/doi.org\/10.1126\/science.ads8473.","journal-title":"Science"},{"key":"771_CR84","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1089\/hum.2023.029","volume":"34","author":"L Xie","year":"2023","unstructured":"Xie L, Gu R, Yang X, Qiu S, Xu Y, Mou J, et al. Universal anti-CD7 CAR-T cells targeting T-ALL and functional analysis of CD7 antigen on T\/CAR-T cells. Hum Gene Ther. 2023;34:1257\u201372. https:\/\/doi.org\/10.1089\/hum.2023.029.","journal-title":"Hum Gene Ther"},{"key":"771_CR85","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41591-024-03282-2","volume":"31","author":"J Pan","year":"2025","unstructured":"Pan J, Tan Y, Shan L, Seery S, Deng B, Ling Z, et al. Allogeneic CD5-specific CAR-T therapy for relapsed\/refractory T-ALL: a phase 1 trial. Nat Med. 2025;31:126\u201336. https:\/\/doi.org\/10.1038\/s41591-024-03282-2.","journal-title":"Nat Med"},{"key":"771_CR86","doi-asserted-by":"publisher","DOI":"10.1038\/s41563-025-02331-6","author":"T Chang","year":"2025","unstructured":"Chang T, Zheng Y, Jiang M, Jia S, Bai J, Zheng Z, et al. Peptide codes for organ-selective mRNA delivery. Nat Mater. 2025. https:\/\/doi.org\/10.1038\/s41563-025-02331-6.","journal-title":"Nat Mater"},{"key":"771_CR87","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-025-02675-z","author":"M Kim","year":"2025","unstructured":"Kim M, Song ES, Chen JC, Chatterjee S, Sun Y, Lee SM, et al. Dual SORT LNPs for multi-organ base editing. Nat Biotechnol [Internet]. 2025. https:\/\/doi.org\/10.1038\/s41587-025-02675-z.","journal-title":"Nat Biotechnol [Internet]."},{"key":"771_CR88","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","volume":"15","author":"Q Cheng","year":"2020","unstructured":"Cheng Q, Wei T, Farbiak L, Johnson LT, Dilliard SA, Siegwart DJ. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR\u2013Cas gene editing. Nat Nanotechnol. 2020;15:313\u201320. https:\/\/doi.org\/10.1038\/s41565-020-0669-6.","journal-title":"Nat Nanotechnol"},{"key":"771_CR89","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","volume":"44","author":"OU Kawalekar","year":"2016","unstructured":"Kawalekar OU, O\u2019Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey AD, et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity. 2016;44:380\u201390. https:\/\/doi.org\/10.1016\/j.immuni.2016.01.021.","journal-title":"Immunity"},{"key":"771_CR90","doi-asserted-by":"publisher","first-page":"10635","DOI":"10.1038\/s41467-024-54877-9","volume":"15","author":"AEI Hamouda","year":"2024","unstructured":"Hamouda AEI, Filtjens J, Brabants E, Kancheva D, Debraekeleer A, Brughmans J, et al. Intratumoral delivery of lipid nanoparticle-formulated mRNA encoding IL-21, IL-7, and 4\u20131BBL induces systemic anti-tumor immunity. Nat Commun. 2024;15:10635. https:\/\/doi.org\/10.1038\/s41467-024-54877-9.","journal-title":"Nat Commun"},{"key":"771_CR91","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41571-023-00811-9","volume":"20","author":"E Kon","year":"2023","unstructured":"Kon E, Ad-El N, Hazan-Halevy I, Stotsky-Oterin L, Peer D. Targeting cancer with mRNA\u2013lipid nanoparticles: key considerations and future prospects. Nat Rev Clin Oncol. 2023;20:739\u201354. https:\/\/doi.org\/10.1038\/s41571-023-00811-9.","journal-title":"Nat Rev Clin Oncol"},{"key":"771_CR92","doi-asserted-by":"publisher","first-page":"2500903","DOI":"10.1002\/smll.202500903","volume":"21","author":"SL Yap","year":"2025","unstructured":"Yap SL, Dyett B, Hobro AJ, Nguyen H, Smith NI, Drummond CJ, et al. The internal nanostructure of lipid nanoparticles influences their diverse cellular uptake pathways. Small. 2025;21:2500903. https:\/\/doi.org\/10.1002\/smll.202500903.","journal-title":"Small"},{"key":"771_CR93","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2307800120","volume":"121","author":"S Chatterjee","year":"2024","unstructured":"Chatterjee S, Kon E, Sharma P, Peer D. Endosomal escape: a bottleneck for LNP-mediated therapeutics. Proc Natl Acad Sci USA. 2024;121:e2307800120. https:\/\/doi.org\/10.1073\/pnas.2307800120.","journal-title":"Proc Natl Acad Sci USA"},{"key":"771_CR94","doi-asserted-by":"publisher","first-page":"4492","DOI":"10.1038\/s41467-019-12508-8","volume":"10","author":"BP Dyett","year":"2019","unstructured":"Dyett BP, Yu H, Strachan J, Drummond CJ, Conn CE. Fusion dynamics of cubosome nanocarriers with model cell membranes. Nat Commun. 2019;10:4492. https:\/\/doi.org\/10.1038\/s41467-019-12508-8.","journal-title":"Nat Commun"},{"key":"771_CR95","doi-asserted-by":"publisher","first-page":"4700","DOI":"10.1038\/s41467-025-60040-9","volume":"16","author":"X Cheng","year":"2025","unstructured":"Cheng X, Zheng X, Tao K, Huo H, Liu Z, Lu X, et al. Freezing induced incorporation of betaine in lipid nanoparticles enhances mRNA delivery. Nat Commun. 2025;16:4700. https:\/\/doi.org\/10.1038\/s41467-025-60040-9.","journal-title":"Nat Commun"},{"key":"771_CR96","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-025-02556-5","author":"MN Patel","year":"2025","unstructured":"Patel MN, Tiwari S, Wang Y, O\u2019Neill S, Wu J, Omo-Lamai S, et al. Safer non-viral DNA delivery using lipid nanoparticles loaded with endogenous anti-inflammatory lipids. Nat Biotechnol. 2025. https:\/\/doi.org\/10.1038\/s41587-025-02556-5.","journal-title":"Nat Biotechnol"},{"key":"771_CR97","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41551-024-01296-2","volume":"9","author":"R Ho\u0142ubowicz","year":"2024","unstructured":"Ho\u0142ubowicz R, Du SW, Felgner J, Smidak R, Choi EH, Palczewska G, et al. Safer and efficient base editing and prime editing via ribonucleoproteins delivered through optimized lipid-nanoparticle formulations. Nat Biomed Eng. 2024;9:57\u201378. https:\/\/doi.org\/10.1038\/s41551-024-01296-2.","journal-title":"Nat Biomed Eng"},{"key":"771_CR98","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41573-023-00859-3","volume":"23","author":"D Bitounis","year":"2024","unstructured":"Bitounis D, Jacquinet E, Rogers MA, Amiji MM. Strategies to reduce the risks of mRNA drug and vaccine toxicity. Nat Rev Drug Discov. 2024;23:281\u2013300. https:\/\/doi.org\/10.1038\/s41573-023-00859-3.","journal-title":"Nat Rev Drug Discov"},{"key":"771_CR99","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/s41565-022-01071-x","volume":"17","author":"J Szebeni","year":"2022","unstructured":"Szebeni J, Storm G, Ljubimova JY, Castells M, Phillips EJ, Turjeman K, et al. Applying lessons learned from nanomedicines to understand rare hypersensitivity reactions to mRNA-based SARS-CoV-2 vaccines. Nat Nanotechnol. 2022;17:337\u201346. https:\/\/doi.org\/10.1038\/s41565-022-01071-x.","journal-title":"Nat Nanotechnol"},{"key":"771_CR100","doi-asserted-by":"publisher","first-page":"4185","DOI":"10.1016\/j.ymthe.2024.10.017","volume":"32","author":"J-H Wang","year":"2024","unstructured":"Wang J-H, Zhan W, Gallagher TL, Gao G. Recombinant adeno-associated virus as a delivery platform for ocular gene therapy: a comprehensive review. Mol Ther. 2024;32:4185\u2013207. https:\/\/doi.org\/10.1016\/j.ymthe.2024.10.017.","journal-title":"Mol Ther"},{"key":"771_CR101","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","volume":"18","author":"D Wang","year":"2019","unstructured":"Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019;18:358\u201378. https:\/\/doi.org\/10.1038\/s41573-019-0012-9.","journal-title":"Nat Rev Drug Discov"},{"key":"771_CR102","doi-asserted-by":"publisher","DOI":"10.3390\/v13071288","volume":"13","author":"W Dong","year":"2021","unstructured":"Dong W, Kantor B. Lentiviral vectors for delivery of gene-editing systems based on CRISPR\/Cas: current state and perspectives. Viruses. 2021;13:1288. https:\/\/doi.org\/10.3390\/v13071288.","journal-title":"Viruses"},{"key":"771_CR103","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1016\/j.gendis.2022.03.007","volume":"10","author":"L Deng","year":"2023","unstructured":"Deng L, Liang P, Cui H. Pseudotyped lentiviral vectors: ready for translation into targeted cancer gene therapy? Genes Dis. 2023;10:1937\u201355. https:\/\/doi.org\/10.1016\/j.gendis.2022.03.007.","journal-title":"Genes Dis"},{"key":"771_CR104","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1016\/j.ymthe.2025.03.056","volume":"33","author":"AM Nisanov","year":"2025","unstructured":"Nisanov AM, Rivera De Jes\u00fas JA, Schaffer DV. Advances in AAV capsid engineering: integrating rational design, directed evolution and machine learning. Mol Ther. 2025;33:1937\u201345. https:\/\/doi.org\/10.1016\/j.ymthe.2025.03.056.","journal-title":"Mol Ther"},{"key":"771_CR105","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01780-w","volume":"9","author":"J-H Wang","year":"2024","unstructured":"Wang J-H, Gessler DJ, Zhan W, Gallagher TL, Gao G. Adeno-associated virus as a delivery vector for gene therapy of human diseases. Sig Transduct Target Ther. 2024;9:78. https:\/\/doi.org\/10.1038\/s41392-024-01780-w.","journal-title":"Sig Transduct Target Ther"},{"key":"771_CR106","doi-asserted-by":"publisher","first-page":"4919","DOI":"10.1016\/j.cell.2021.08.028","volume":"184","author":"M Tabebordbar","year":"2021","unstructured":"Tabebordbar M, Lagerborg KA, Stanton A, King EM, Ye S, Tellez L, et al. Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species. Cell. 2021;184:4919-4938.e22. https:\/\/doi.org\/10.1016\/j.cell.2021.08.028.","journal-title":"Cell"},{"key":"771_CR107","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.omtm.2020.12.006","volume":"20","author":"M Nonnenmacher","year":"2021","unstructured":"Nonnenmacher M, Wang W, Child MA, Ren X-Q, Huang C, Ren AZ, et al. Rapid evolution of blood-brain-barrier-penetrating AAV capsids by RNA-driven biopanning. Mol Ther Methods Clin Dev. 2021;20:366\u201378. https:\/\/doi.org\/10.1016\/j.omtm.2020.12.006.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"771_CR108","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1038\/s41591-025-03937-8","volume":"31","author":"J Feng","year":"2025","unstructured":"Feng J, Huo D, Hong R, Jin X, Cao H, Shao M, et al. Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial. Nat Med. 2025;31:3725\u201336. https:\/\/doi.org\/10.1038\/s41591-025-03937-8.","journal-title":"Nat Med"},{"key":"771_CR109","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/s41551-024-01341-0","volume":"9","author":"A Rosales","year":"2025","unstructured":"Rosales A, Blondel LO, Hull J, Gao Q, Aykun N, Peek JL, et al. Evolving adeno-associated viruses for gene transfer to the kidney via cross-species cycling of capsid libraries. Nat Biomed Eng. 2025;9:1086\u2013100. https:\/\/doi.org\/10.1038\/s41551-024-01341-0.","journal-title":"Nat Biomed Eng"},{"key":"771_CR110","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.immuni.2025.01.009","volume":"58","author":"WA Nyberg","year":"2025","unstructured":"Nyberg WA, Wang CH, Ark J, Liu C, Clouden S, Qualls A, et al. In vivo engineering of murine T cells using the evolved adeno-associated virus variant Ark313. Immunity. 2025;58:499-512.e7. https:\/\/doi.org\/10.1016\/j.immuni.2025.01.009.","journal-title":"Immunity"},{"key":"771_CR111","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26178497","volume":"26","author":"A Arrasate","year":"2025","unstructured":"Arrasate A, Lopez-Robles C, Zuazo M, Banos-Mateos S, Martin C, Lamsfus-Calle A, et al. Lentiviral vectors: from wild-type viruses to efficient multi-functional delivery vectors. Int J Mol Sci. 2025;26:8497. https:\/\/doi.org\/10.3390\/ijms26178497.","journal-title":"Int J Mol Sci"},{"key":"771_CR112","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018924","author":"A Odak","year":"2023","unstructured":"Odak A, Yuan H, Feucht J, Cantu VA, Mansilla-Soto J, Kogel F, et al. Novel extragenic genomic safe harbors for precise therapeutic T cell engineering. Blood. 2023. https:\/\/doi.org\/10.1182\/blood.2022018924.","journal-title":"Blood"},{"key":"771_CR113","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-07183-x","volume":"23","author":"P Safarzadeh Kozani","year":"2025","unstructured":"Safarzadeh Kozani P, Safarzadeh Kozani P. Preventing secondary primary malignancies (SPMs) in CAR-T cell therapy through site-specific transgene integration into genomic safe harbors (GSHs). J Transl Med. 2025;23:1155. https:\/\/doi.org\/10.1186\/s12967-025-07183-x.","journal-title":"J Transl Med"},{"key":"771_CR114","doi-asserted-by":"publisher","first-page":"8463","DOI":"10.1128\/JVI.72.11.8463-8471.1998","volume":"72","author":"T Dull","year":"1998","unstructured":"Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, et al. A third-generation lentivirus vector with a conditional packaging system. J Virol. 1998;72:8463\u201371. https:\/\/doi.org\/10.1128\/JVI.72.11.8463-8471.1998.","journal-title":"J Virol"},{"key":"771_CR115","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1056\/NEJMoa2407376","volume":"392","author":"C Booth","year":"2025","unstructured":"Booth C, Sevilla J, Almarza E, Kuo CY, Zubicaray J, Terrazas D, et al. Lentiviral gene therapy for severe leukocyte adhesion deficiency type 1. N Engl J Med. 2025;392:1698\u2013709. https:\/\/doi.org\/10.1056\/NEJMoa2407376.","journal-title":"N Engl J Med"},{"key":"771_CR116","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1038\/s41434-023-00406-0","volume":"30","author":"NAM Nafchi","year":"2023","unstructured":"Nafchi NAM, Chilcott EM, Brown S, Fuller HR, Bowerman M, Y\u00e1\u00f1ez-Mu\u00f1oz RJ. Enhanced expression of the human survival motor neuron 1 gene from a codon-optimised cDNA transgene in vitro and in vivo. Gene Ther. 2023;30:812\u201325. https:\/\/doi.org\/10.1038\/s41434-023-00406-0.","journal-title":"Gene Ther"},{"key":"771_CR117","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1038\/s41596-024-01119-3","volume":"20","author":"X Zheng","year":"2025","unstructured":"Zheng X, Thompson PC, White CM, Jin X. Massively parallel in vivo Perturb-seq screening. Nat Protoc. 2025;20:1733\u201367. https:\/\/doi.org\/10.1038\/s41596-024-01119-3.","journal-title":"Nat Protoc"},{"key":"771_CR118","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1089\/hum.2019.143","volume":"30","author":"SJ Aronson","year":"2019","unstructured":"Aronson SJ, Veron P, Collaud F, Hubert A, Delahais V, Honnet G, et al. Prevalence and relevance of pre-existing anti-adeno-associated virus immunity in the context of gene therapy for Crigler\u2013Najjar syndrome. Hum Gene Ther. 2019;30:1297\u2013305. https:\/\/doi.org\/10.1089\/hum.2019.143.","journal-title":"Hum Gene Ther"},{"key":"771_CR119","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.tibtech.2023.04.002","volume":"41","author":"Z Jiang","year":"2023","unstructured":"Jiang Z, Dalby PA. Challenges in scaling up AAV-based gene therapy manufacturing. Trends Biotechnol. 2023;41:1268\u201381. https:\/\/doi.org\/10.1016\/j.tibtech.2023.04.002.","journal-title":"Trends Biotechnol"},{"key":"771_CR120","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1002\/bit.70052","volume":"122","author":"A Andaluz","year":"2025","unstructured":"Andaluz A, Monteverde B, Vera K, Tse B, Gajic I, Froelich C, et al. Accelerated adeno associated virus upstream process development from high\u2010throughput systems to clinical scale. Biotechnol Bioeng. 2025;122:3051\u201360. https:\/\/doi.org\/10.1002\/bit.70052.","journal-title":"Biotechnol Bioeng"},{"key":"771_CR121","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12102265","volume":"12","author":"A Arrasate","year":"2024","unstructured":"Arrasate A, Bravo I, Lopez-Robles C, Arbelaiz-Sarasola A, Ugalde M, Meijueiro ML, et al. Establishment and characterization of a stable producer cell line generation platform for the manufacturing of clinical-grade lentiviral vectors. Biomedicines. 2024;12:2265. https:\/\/doi.org\/10.3390\/biomedicines12102265.","journal-title":"Biomedicines"},{"key":"771_CR122","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s40291-024-00749-3","volume":"28","author":"SJ Keam","year":"2024","unstructured":"Keam SJ. Afamitresgene Autoleucel: first approval. Mol Diagn Ther. 2024;28:861\u20136. https:\/\/doi.org\/10.1007\/s40291-024-00749-3.","journal-title":"Mol Diagn Ther"},{"key":"771_CR123","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2025.101425","volume":"33","author":"B Diez","year":"2025","unstructured":"Diez B, Calvi\u00f1o C, Fern\u00e1ndez-Garc\u00eda M, Rodr\u00edguez-M\u00e1rquez P, Rodr\u00edguez-D\u00edaz S, Mart\u00ednez-Turillas R, et al. Generation and GMP scale-up of human CAR-T cells using non-viral Sleeping Beauty transposons for B cell malignances. Mol Ther Methods Clin Dev. 2025;33:101425. https:\/\/doi.org\/10.1016\/j.omtm.2025.101425.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"771_CR124","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1038\/s41375-025-02585-8","volume":"39","author":"G Ottaviano","year":"2025","unstructured":"Ottaviano G, Qasim W. Current landscape of vector safety and genotoxicity after hematopoietic stem or immune cell gene therapy. Leukemia. 2025;39:1325\u201333. https:\/\/doi.org\/10.1038\/s41375-025-02585-8.","journal-title":"Leukemia"},{"key":"771_CR125","doi-asserted-by":"publisher","first-page":"5702","DOI":"10.1182\/bloodadvances.2020002229","volume":"4","author":"AM Frank","year":"2020","unstructured":"Frank AM, Braun AH, Scheib L, Agarwal S, Schneider IC, Fusil F, et al. Combining T-cell-specific activation and in vivo gene delivery through CD3-targeted lentiviral vectors. Blood Adv. 2020;4:5702\u201315. https:\/\/doi.org\/10.1182\/bloodadvances.2020002229.","journal-title":"Blood Adv"},{"key":"771_CR126","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/j.ymthe.2025.01.037","volume":"33","author":"B Liu","year":"2025","unstructured":"Liu B, Sajiki Y, Littlefield N, Hu Y, Stuart WD, Sridharan A, et al. PBAE-PEG-based lipid nanoparticles for lung cell-specific gene delivery. Mol Ther. 2025;33:1154\u201365. https:\/\/doi.org\/10.1016\/j.ymthe.2025.01.037.","journal-title":"Mol Ther"},{"key":"771_CR127","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25031739","volume":"25","author":"S Yousefi Adlsadabad","year":"2024","unstructured":"Yousefi Adlsadabad S, Hanrahan JW, Kakkar A. mRNA delivery: challenges and advances through polymeric soft nanoparticles. IJMS. 2024;25:1739. https:\/\/doi.org\/10.3390\/ijms25031739.","journal-title":"IJMS"},{"key":"771_CR128","doi-asserted-by":"publisher","DOI":"10.1002\/smsc.202400248","author":"M Jain","year":"2024","unstructured":"Jain M, Yu X, Schneck JP, Green JJ. Nanoparticle targeting strategies for lipid and polymer-based gene delivery to immune cells in vivo. Small Sci. 2024. https:\/\/doi.org\/10.1002\/smsc.202400248.","journal-title":"Small Sci."},{"key":"771_CR129","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25163731","volume":"25","author":"A Zieli\u0144ska","year":"2020","unstructured":"Zieli\u0144ska A, Carreir\u00f3 F, Oliveira AM, Neves A, Pires B, Venkatesh DN, et al. Polymeric nanoparticles: production, characterization, toxicology and ecotoxicology. Molecules. 2020;25:3731. https:\/\/doi.org\/10.3390\/molecules25163731.","journal-title":"Molecules"},{"key":"771_CR130","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-07249-w","volume":"23","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Li Y, Yang K, Liu W, Zhao S, Tang Y, et al. Synergistic innovations of nanomedicine in lymphoma treatment: a systematic review. J Transl Med. 2025;23:1389. https:\/\/doi.org\/10.1186\/s12967-025-07249-w.","journal-title":"J Transl Med"},{"key":"771_CR131","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.tips.2025.11.001","volume":"47","author":"Y-R Li","year":"2026","unstructured":"Li Y-R, Yang L. Autologous, allogeneic, in vivo CAR for autoimmune diseases. Trends Pharmacol Sci. 2026;47:11\u20134. https:\/\/doi.org\/10.1016\/j.tips.2025.11.001.","journal-title":"Trends Pharmacol Sci"},{"key":"771_CR132","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19486-2","volume":"11","author":"NN Parayath","year":"2020","unstructured":"Parayath NN, Stephan SB, Koehne AL, Nelson PS, Stephan MT. In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo. Nat Commun. 2020;11:6080. https:\/\/doi.org\/10.1038\/s41467-020-19486-2.","journal-title":"Nat Commun"},{"key":"771_CR133","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41576-021-00439-4","volume":"23","author":"K Paunovska","year":"2022","unstructured":"Paunovska K, Loughrey D, Dahlman JE. Drug delivery systems for RNA therapeutics. Nat Rev Genet. 2022;23:265\u201380. https:\/\/doi.org\/10.1038\/s41576-021-00439-4.","journal-title":"Nat Rev Genet"},{"key":"771_CR134","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02476-7","volume":"24","author":"D Shang","year":"2025","unstructured":"Shang D, Zhou Z, Shi R, Wang Z, Zhang P, Peng F, et al. Nanoparticle-based strategy in CAR-T cell immunotherapy: challenges, implications, and perspectives. Mol Cancer. 2025;24:281. https:\/\/doi.org\/10.1186\/s12943-025-02476-7.","journal-title":"Mol Cancer"},{"key":"771_CR135","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.jconrel.2024.04.040","volume":"370","author":"VV Inamdar","year":"2024","unstructured":"Inamdar VV, Hao S, Stephan SB, Stephan MT. Biomaterial-based scaffolds for direct in situ programming of tumor-infiltrating T lymphocytes. J Control Release. 2024;370:310\u20137. https:\/\/doi.org\/10.1016\/j.jconrel.2024.04.040.","journal-title":"J Control Release"},{"key":"771_CR136","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1038\/s41587-022-01245-x","volume":"40","author":"P Agarwalla","year":"2022","unstructured":"Agarwalla P, Ogunnaike EA, Ahn S, Froehlich KA, Jansson A, Ligler FS, et al. Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells. Nat Biotechnol. 2022;40:1250\u20138. https:\/\/doi.org\/10.1038\/s41587-022-01245-x.","journal-title":"Nat Biotechnol"},{"key":"771_CR137","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2024.122580","volume":"308","author":"S Pandit","year":"2024","unstructured":"Pandit S, Agarwalla P, Song F, Jansson A, Dotti G, Brudno Y. Implantable CAR T cell factories enhance solid tumor treatment. Biomaterials. 2024;308:122580. https:\/\/doi.org\/10.1016\/j.biomaterials.2024.122580.","journal-title":"Biomaterials"},{"key":"771_CR138","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1038\/s41590-025-02252-1","volume":"26","author":"MS Eggeb\u00f8","year":"2025","unstructured":"Eggeb\u00f8 MS, Heinzelbecker J, Palashati H, Chandler N, Tran TT, Li Y, et al. TCR-engineered T cells targeting a shared \u03b2-catenin mutation eradicate solid tumors. Nat Immunol. 2025;26:1726\u201336. https:\/\/doi.org\/10.1038\/s41590-025-02252-1.","journal-title":"Nat Immunol"},{"key":"771_CR139","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1097\/CM9.0000000000003111","volume":"137","author":"Y Liu","year":"2024","unstructured":"Liu Y, Dong M, Chu Y, Zhou L, You Y, Pang X, et al. Dawn of CAR-T cell therapy in autoimmune diseases. Chin Med J (Engl). 2024;137:1140\u201350. https:\/\/doi.org\/10.1097\/CM9.0000000000003111.","journal-title":"Chin Med J (Engl)"},{"key":"771_CR140","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1615212","volume":"16","author":"AA Alsaieedi","year":"2025","unstructured":"Alsaieedi AA, Zaher KA. Tracing the development of CAR-T cell design: from concept to next-generation platforms. Front Immunol. 2025;16:1615212. https:\/\/doi.org\/10.3389\/fimmu.2025.1615212.","journal-title":"Front Immunol"},{"key":"771_CR141","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006292","volume":"11","author":"KR Michels","year":"2023","unstructured":"Michels KR, Sheih A, Hernandez SA, Brandes AH, Parrilla D, Irwin B, et al. Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering. J Immunother Cancer. 2023;11:e006292. https:\/\/doi.org\/10.1136\/jitc-2022-006292.","journal-title":"J Immunother Cancer"},{"key":"771_CR142","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1182\/blood.2024024523","volume":"144","author":"CJ Nicolai","year":"2024","unstructured":"Nicolai CJ, Parker MH, Qin J, Tang W, Ulrich-Lewis JT, Gottschalk RJ, et al. In vivo CAR T-cell generation in nonhuman primates using lentiviral vectors displaying a multidomain fusion ligand. Blood. 2024;144:977\u201387. https:\/\/doi.org\/10.1182\/blood.2024024523.","journal-title":"Blood"},{"key":"771_CR143","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1352805","volume":"15","author":"V Albarr\u00e1n","year":"2024","unstructured":"Albarr\u00e1n V, San Rom\u00e1n M, Pozas J, Chamorro J, Rosero DI, Guerrero P, et al. Adoptive T cell therapy for solid tumors: Current landscape and future challenges. Front Immunol. 2024;15:1352805. https:\/\/doi.org\/10.3389\/fimmu.2024.1352805.","journal-title":"Front Immunol"},{"key":"771_CR144","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/s41592-022-01436-z","volume":"19","author":"CS Dobson","year":"2022","unstructured":"Dobson CS, Reich AN, Gaglione S, Smith BE, Kim EJ, Dong J, et al. Antigen identification and high-throughput interaction mapping by reprogramming viral entry. Nat Methods. 2022;19:449\u201360. https:\/\/doi.org\/10.1038\/s41592-022-01436-z.","journal-title":"Nat Methods"},{"key":"771_CR145","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1056\/NEJMc2509522","volume":"393","author":"Q Wang","year":"2025","unstructured":"Wang Q, Xiao ZX, Zheng X, Wang G, Yang L, Shi L, et al. In vivo CD19 CAR T-cell therapy for refractory systemic lupus erythematosus. N Engl J Med. 2025;393:1542\u20134. https:\/\/doi.org\/10.1056\/NEJMc2509522.","journal-title":"N Engl J Med"},{"key":"771_CR146","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1038\/nmeth.1514","volume":"7","author":"B Anliker","year":"2010","unstructured":"Anliker B, Abel T, Kneissl S, Hlavaty J, Caputi A, Brynza J, et al. Specific gene transfer to neurons, endothelial cells and hematopoietic progenitors with lentiviral vectors. Nat Methods. 2010;7:929\u201335. https:\/\/doi.org\/10.1038\/nmeth.1514.","journal-title":"Nat Methods"},{"key":"771_CR147","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379:64\u201373. https:\/\/doi.org\/10.1056\/NEJMra1706169.","journal-title":"N Engl J Med"},{"key":"771_CR148","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1038\/s41591-024-03478-6","volume":"31","author":"JK Jadlowsky","year":"2025","unstructured":"Jadlowsky JK, Hexner EO, Marshall A, Grupp SA, Frey NV, Riley JL, et al. Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies. Nat Med. 2025;31:1134\u201344. https:\/\/doi.org\/10.1038\/s41591-024-03478-6.","journal-title":"Nat Med"},{"key":"771_CR149","doi-asserted-by":"publisher","first-page":"40798","DOI":"10.1021\/acsnano.5c09138","volume":"19","author":"J-H Han","year":"2025","unstructured":"Han J-H, Fagan E, Yeom K, Park J-H. In situ chimeric antigen receptor macrophage therapy via co-delivery of mRNA and immunostimulant. ACS Nano. 2025;19:40798\u2013816. https:\/\/doi.org\/10.1021\/acsnano.5c09138.","journal-title":"ACS Nano"},{"key":"771_CR150","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.abm0594","volume":"375","author":"JG Rurik","year":"2022","unstructured":"Rurik JG, Tomb\u00e1cz I, Yadegari A, M\u00e9ndez Fern\u00e1ndez PO, Shewale SV, Li L, et al. CAR T cells produced in vivo to treat cardiac injury. Science. 2022;375:91\u20136. https:\/\/doi.org\/10.1126\/science.abm0594.","journal-title":"Science"},{"key":"771_CR151","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0281735","volume":"18","author":"P Sawaisorn","year":"2023","unstructured":"Sawaisorn P, Atjanasuppat K, Uaesoontrachoon K, Rattananon P, Treesuppharat W, Hongeng S, et al. Comparison of the efficacy of second and third generation lentiviral vector transduced CAR CD19 T cells for use in the treatment of acute lymphoblastic leukemia both in vitro and in vivo models. PLoS ONE. 2023;18:e0281735. https:\/\/doi.org\/10.1371\/journal.pone.0281735.","journal-title":"PLoS ONE"},{"key":"771_CR152","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/j.ccell.2022.11.006","volume":"40","author":"A Smole","year":"2022","unstructured":"Smole A, Benton A, Poussin MA, Eiva MA, Mezzanotte C, Camisa B, et al. Expression of inducible factors reprograms CAR-T cells for enhanced function and safety. Cancer Cell. 2022;40:1470-1487.e7. https:\/\/doi.org\/10.1016\/j.ccell.2022.11.006.","journal-title":"Cancer Cell"},{"key":"771_CR153","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-011698","volume":"13","author":"D Andreu-Sanz","year":"2025","unstructured":"Andreu-Sanz D, Gregor L, Carlini E, Scarcella D, Marr C, Kobold S. Predictive value of preclinical models for CAR-T cell therapy clinical trials: a systematic review and meta-analysis. J Immunother Cancer. 2025;13:e011698. https:\/\/doi.org\/10.1136\/jitc-2025-011698.","journal-title":"J Immunother Cancer"},{"key":"771_CR154","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrc.2016.91","volume":"16","author":"L Zitvogel","year":"2016","unstructured":"Zitvogel L, Pitt JM, Daill\u00e8re R, Smyth MJ, Kroemer G. Mouse models in oncoimmunology. Nat Rev Cancer. 2016;16:759\u201373. https:\/\/doi.org\/10.1038\/nrc.2016.91.","journal-title":"Nat Rev Cancer"},{"key":"771_CR155","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41571-022-00721-2","volume":"20","author":"J Chuprin","year":"2023","unstructured":"Chuprin J, Buettner H, Seedhom MO, Greiner DL, Keck JG, Ishikawa F, et al. Humanized mouse models for immuno-oncology research. Nat Rev Clin Oncol. 2023;20:192\u2013206. https:\/\/doi.org\/10.1038\/s41571-022-00721-2.","journal-title":"Nat Rev Clin Oncol"},{"key":"771_CR156","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0236614","volume":"16","author":"S Yanagawa","year":"2021","unstructured":"Yanagawa S, Tahara H, Shirouzu T, Kawai S, Tanaka Y, Ide K, et al. Development of a humanized mouse model to analyze antibodies specific for human leukocyte antigen (HLA). PLoS ONE. 2021;16:e0236614. https:\/\/doi.org\/10.1371\/journal.pone.0236614.","journal-title":"PLoS ONE"},{"key":"771_CR157","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.stem.2022.06.014","volume":"29","author":"R Jing","year":"2022","unstructured":"Jing R, Scarfo I, Najia MA, Lummertz Da Rocha E, Han A, Sanborn M, et al. EZH1 repression generates mature iPSC-derived CAR T cells with enhanced antitumor activity. Cell Stem Cell. 2022;29:1181-1196.e6. https:\/\/doi.org\/10.1016\/j.stem.2022.06.014.","journal-title":"Cell Stem Cell"},{"key":"771_CR158","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3390\/jox14010006","volume":"14","author":"RN Sewduth","year":"2024","unstructured":"Sewduth RN, Georgelou K. Relevance of carcinogen-induced preclinical cancer models. JoX. 2024;14:96\u2013109. https:\/\/doi.org\/10.3390\/jox14010006.","journal-title":"JoX"},{"key":"771_CR159","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s12276-024-01191-5","volume":"56","author":"S Mun","year":"2024","unstructured":"Mun S, Lee HJ, Kim P. Rebuilding the microenvironment of primary tumors in humans: a focus on stroma. Exp Mol Med. 2024;56:527\u201348. https:\/\/doi.org\/10.1038\/s12276-024-01191-5.","journal-title":"Exp Mol Med"},{"key":"771_CR160","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-48528-0","volume":"13","author":"J Seigner","year":"2023","unstructured":"Seigner J, Zajc CU, D\u00f6tsch S, Eigner C, Laurent E, Busch DH, et al. Solving the mystery of the FMC63-CD19 affinity. Sci Rep. 2023;13:23024. https:\/\/doi.org\/10.1038\/s41598-023-48528-0.","journal-title":"Sci Rep"},{"key":"771_CR161","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adr2531","volume":"17","author":"L Tecedor","year":"2025","unstructured":"Tecedor L, Chen YH, Leib DE, Ranum PT, Keiser MS, Lewandowski BC, et al. An AAV variant selected through NHP screens robustly transduces the brain and drives secreted protein expression in NHPs and mice. Sci Transl Med. 2025;17:eadr2531. https:\/\/doi.org\/10.1126\/scitranslmed.adr2531.","journal-title":"Sci Transl Med"},{"key":"771_CR162","doi-asserted-by":"publisher","DOI":"10.34133\/2021\/9898769","volume":"2021","author":"M Huang","year":"2021","unstructured":"Huang M, Yang J, Li P, Chen Y. Embryo-engineered nonhuman primate models: progress and gap to translational medicine. Research. 2021;2021:2021\/9898769. https:\/\/doi.org\/10.34133\/2021\/9898769.","journal-title":"Research"},{"key":"771_CR163","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1158\/1538-7445.AM2024-48","volume":"84","author":"ET Beura","year":"2024","unstructured":"Beura ET, Latimer HJ, Wong D, Obrigewitch J, Warr AJ, Dong S, et al. Abstract 48: T cell-specific in vivo transduction with preclinical candidate KLN-1010 generates BCMA directed CAR T cells with potent anti-multiple myeloma activity. Cancer Res. 2024;84:48\u201348. https:\/\/doi.org\/10.1158\/1538-7445.AM2024-48.","journal-title":"Cancer Res"},{"key":"771_CR164","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11:69. https:\/\/doi.org\/10.1038\/s41408-021-00459-7.","journal-title":"Blood Cancer J"},{"key":"771_CR165","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1016\/j.stem.2025.07.014","volume":"32","author":"S Zhao","year":"2025","unstructured":"Zhao S, Li R, Xia Y, Wang X, Liu Z, Chu Q, et al. Targeting ECM-producing cells with CAR-T therapy alleviates fibrosis in chronic kidney disease. Cell Stem Cell. 2025;32:1390-1402.e9. https:\/\/doi.org\/10.1016\/j.stem.2025.07.014.","journal-title":"Cell Stem Cell"},{"key":"771_CR166","doi-asserted-by":"publisher","DOI":"10.34133\/research.0917","volume":"8","author":"M Lai","year":"2025","unstructured":"Lai M, Shao W, Mao J, Ye Q. Revolution in cell therapy: in vivo chimeric-antigen-receptor-T-cell therapy breakthroughs and promises for the future. Research. 2025;8:0917. https:\/\/doi.org\/10.34133\/research.0917.","journal-title":"Research"},{"key":"771_CR167","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202303261","volume":"35","author":"Y Zong","year":"2023","unstructured":"Zong Y, Lin Y, Wei T, Cheng Q. Lipid nanoparticle (LNP) enables mRNA delivery for cancer therapy. Adv Mater. 2023;35:2303261. https:\/\/doi.org\/10.1002\/adma.202303261.","journal-title":"Adv Mater"},{"key":"771_CR168","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102209","volume":"6","author":"Z Zhang","year":"2025","unstructured":"Zhang Z, Ma B, Li B, Li Z, Gao M, Zhao H, et al. Cardiolipin-mimic lipid nanoparticles without antibody modification delivered senolytic in vivo CAR-T therapy for inflamm-aging. Cell Rep Med. 2025;6:102209. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102209.","journal-title":"Cell Rep Med"},{"key":"771_CR169","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1158\/2159-8290.CD-23-1334","volume":"14","author":"AJ Schoenfeld","year":"2024","unstructured":"Schoenfeld AJ, Lee SM, De Sp\u00e9ville BD, Gettinger SN, H\u00e4fliger S, Sukari A, et al. Lifileucel, an autologous tumor-infiltrating lymphocyte monotherapy, in patients with advanced non-small cell lung cancer resistant to immune checkpoint inhibitors. Cancer Discov. 2024;14:1389\u2013402. https:\/\/doi.org\/10.1158\/2159-8290.CD-23-1334.","journal-title":"Cancer Discov"},{"key":"771_CR170","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1056\/NEJMoa2411507","volume":"392","author":"K Perica","year":"2025","unstructured":"Perica K, Jain N, Scordo M, Patel R, Eren OC, Patel U, et al. CD4+ T-cell lymphoma harboring a chimeric antigen receptor integration in TP53. N Engl J Med. 2025;392:577\u201383. https:\/\/doi.org\/10.1056\/NEJMoa2411507.","journal-title":"N Engl J Med"},{"key":"771_CR171","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-022-02327-z","volume":"41","author":"K Pan","year":"2022","unstructured":"Pan K, Farrukh H, Chittepu VCSR, Xu H, Pan C, Zhu Z. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. J Exp Clin Cancer Res. 2022;41:119. https:\/\/doi.org\/10.1186\/s13046-022-02327-z.","journal-title":"J Exp Clin Cancer Res"},{"key":"771_CR172","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202412227","volume":"36","author":"Z Hu","year":"2024","unstructured":"Hu Z, Tan H, Ye Y, Xu W, Gao J, Liu L, et al. NIR\u2010actuated ferroptosis nanomotor for enhanced tumor penetration and therapy. Adv Mater. 2024;36:2412227. https:\/\/doi.org\/10.1002\/adma.202412227.","journal-title":"Adv Mater"},{"key":"771_CR173","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1548630","volume":"16","author":"L Pinot","year":"2025","unstructured":"Pinot L, Sa\u00dfor A, M\u00f6ker N, Zhang C, Verhoeyen E, Hidalgo JV, et al. Transduction of \u03b3\u03b4 T cells with Baboon envelope pseudotyped lentiviral vector encoding chimeric antigen receptors for translational and clinical applications. Front Immunol. 2025;16:1548630. https:\/\/doi.org\/10.3389\/fimmu.2025.1548630.","journal-title":"Front Immunol"},{"key":"771_CR174","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1038\/s41565-025-01924-1","volume":"20","author":"Z Zhao","year":"2025","unstructured":"Zhao Z, Li Q, Qu C, Jiang Z, Jia G, Lan G, et al. A collagenase nanogel backpack improves CAR-T cell therapy outcomes in pancreatic cancer. Nat Nanotechnol. 2025;20:1131\u201341. https:\/\/doi.org\/10.1038\/s41565-025-01924-1.","journal-title":"Nat Nanotechnol"},{"key":"771_CR175","doi-asserted-by":"publisher","DOI":"10.1172\/JCI166028","volume":"133","author":"JE Jaspers","year":"2023","unstructured":"Jaspers JE, Khan JF, Godfrey WD, Lopez AV, Ciampricotti M, Rudin CM, et al. IL-18\u2013secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models. J Clin Investig. 2023;133:e166028. https:\/\/doi.org\/10.1172\/JCI166028.","journal-title":"J Clin Investig"},{"key":"771_CR176","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa2408771","volume":"392","author":"J Svoboda","year":"2025","unstructured":"Svoboda J, Landsburg DJ, Gerson J, Nasta SD, Barta SK, Chong EA, et al. Enhanced CAR T-cell therapy for lymphoma after previous failure. N Engl J Med. 2025;392:1824\u201335. https:\/\/doi.org\/10.1056\/NEJMoa2408771.","journal-title":"N Engl J Med"},{"key":"771_CR177","doi-asserted-by":"publisher","unstructured":"Wang Y, Zhao H, Cochran E, Gorgievski M, Prod\u2019homme T, McCreedy B, et al. 1237 In vivo programming of myeloid cells by mRNA mediated delivery of novel Fca fusion receptor activates anti-tumor immunity. Regular and Young Investigator Award Abstracts [Internet]. BMJ Publishing Group Ltd; 2022 [cited 2025 Dec 5]. p. A1283. https:\/\/doi.org\/10.1136\/jitc-2022-SITC2022.1237.","DOI":"10.1136\/jitc-2022-SITC2022.1237"},{"key":"771_CR178","doi-asserted-by":"publisher","DOI":"10.1002\/btpr.70045","volume":"41","author":"JR Egan","year":"2025","unstructured":"Egan JR, Mar\u00ed\u2010Buy\u00e9 N, Ben\u00edtez\u2010Cano EV, Costa M, Wanika L, Chappell MJ, et al. A digital shadow of CAR T cell expansion in a perfusion bioreactor: informing optimal harvest times for autologous cell therapy. Biotechnol Prog. 2025;41:e70045. https:\/\/doi.org\/10.1002\/btpr.70045.","journal-title":"Biotechnol Prog"},{"key":"771_CR179","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70101","volume":"17","author":"SJ Kim","year":"2024","unstructured":"Kim SJ, Mugundu GM, Singh AP. Translational PK\u2013PD model for in vivo CAR\u2010T\u2010cell therapy delivered using CAR mRNA\u2010loaded polymeric nanoparticle vector. Clin Transl Sci. 2024;17:e70101. https:\/\/doi.org\/10.1111\/cts.70101.","journal-title":"Clin Transl Sci"},{"key":"771_CR180","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1002\/ajh.70131","volume":"101","author":"M Yu","year":"2026","unstructured":"Yu M, Yang T, Ding S, Hu Y. Strategies to enhance CAR \u2010T cell persistence in hematologic malignancies: from molecular design to clinical optimization. Am J Hematol. 2026;101:318\u201336. https:\/\/doi.org\/10.1002\/ajh.70131.","journal-title":"Am J Hematol"},{"key":"771_CR181","doi-asserted-by":"publisher","DOI":"10.64898\/2025.12.12.694033","author":"A Chow","year":"2025","unstructured":"Chow A, Chu H, Li R, Nalbant BN, Dozic AV, Kida LC, et al. Sequence and structural determinants of efficacious de novo chimeric antigen receptors [Internet]. Bioengineering. 2025. https:\/\/doi.org\/10.64898\/2025.12.12.694033.","journal-title":"Bioengineering"},{"key":"771_CR182","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.125.076321","author":"M Zhang","year":"2025","unstructured":"Zhang M, Qin Y, Zhou T, Liu M, Tang T, Xia N, et al. Engineered regulatory T Lymphocytes promote infarcted heart repair. Circulation. 2025. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.125.076321.","journal-title":"Circulation"},{"key":"771_CR183","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. \u2018Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020;19:185\u201399. https:\/\/doi.org\/10.1038\/s41573-019-0051-2.","journal-title":"Nat Rev Drug Discov"},{"key":"771_CR184","doi-asserted-by":"publisher","DOI":"10.1101\/2025.02.25.640143","author":"CN Yashaswini","year":"2025","unstructured":"Yashaswini CN, Cogliati B, Qin T, To T, Williamson T, Papp TE, et al. In vivo anti-FAP CAR T therapy reduces fibrosis and restores liver homeostasis in metabolic dysfunction-associated steatohepatitis [Internet]. Cell Biol. 2025. https:\/\/doi.org\/10.1101\/2025.02.25.640143.","journal-title":"Cell Biol"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-026-00771-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-026-00771-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-026-00771-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T11:46:34Z","timestamp":1779795994000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-026-00771-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":184,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["771"],"URL":"https:\/\/doi.org\/10.1007\/s40259-026-00771-3","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"assertion":[{"value":"18 February 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Xiaoyi Dong, Wei Yan, Xinmiao Long, and Minghua Wu declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials, code availability"}},{"value":"X.D. drafted the manuscript and designed the figures. M.W. and X.L. conceived and designed the manuscript. X.D. and M.W. revised the manuscript. W.Y. provided language polishing of the manuscript. M.W. and W.Y. supervised the manuscript and provided funding support. All the authors have read and approved the final manuscript.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}